BioNTech SE ADR (NASDAQ:BNTX) has a beta value of 1.26 and has seen 1.63 million shares traded in the recent trading session. The company, currently valued at $27.99B, closed the recent trade at $116.62 per share which meant it gained $11.94 on the day or 11.41% during that session. The BNTX stock price is -12.75% off its 52-week high price of $131.49 and 34.38% above the 52-week low of $76.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.12 million shares traded. The 3-month trading volume is 902.79K shares.
The consensus among analysts is that BioNTech SE ADR (BNTX) is Buy stock at the moment, with a recommendation rating of 1.50. 2 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 13 have rated it as a Hold, with 9 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -2.35.
BioNTech SE ADR (NASDAQ:BNTX) trade information
Sporting 11.41% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the BNTX stock price touched $116.62 or saw a rise of 3.08%. Year-to-date, BioNTech SE ADR shares have moved 2.34%, while the 5-day performance has seen it change 17.80%. Over the past 30 days, the shares of BioNTech SE ADR (NASDAQ:BNTX) have changed 15.88%. Short interest in the company has seen 3.63 million shares shorted with days to cover at 3.92.
Wall Street analysts have a consensus price target for the stock at $126, which means that the shares’ value could jump 7.44% from the levels at last check today.. The projected low price target is $121.0 while the price target rests at a high of $145.0. In that case, then, we find that the latest price level in today’s session is -24.34% off the targeted high while a plunge would see the stock gain -3.76% from the levels at last check today..
BioNTech SE ADR (BNTX) estimates and forecasts
The company’s shares have gained 4.34% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -23.14%.
10 analysts offering their estimates for the company have set an average revenue estimate of 161.67M for the current quarter. 10 have an estimated revenue figure of 131.45M for the next ending quarter. Year-ago sales stood 187.6M and 128.7M respectively for this quarter and the next, and analysts expect sales will shrink by -13.82% for the current quarter and -23.14% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -25.87% over the past 5 years. Earnings growth for 2025 is a modest -91.92% while over the next 5 years, the company’s earnings are expected to decrease by -17.68%.
BNTX Dividends
BioNTech SE ADR is expected to release its next earnings report on 2025-Mar-09 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BioNTech SE ADR (NASDAQ:BNTX)’s Major holders
Insiders own 63.23% of the company shares, while shares held by institutions stand at 21.88% with a share float percentage of 59.51%. Investors are also buoyed by the number of investors in a company, with BioNTech SE ADR having a total of 492.0 institutions that hold shares in the company. The top two institutional holders are BAILLIE GIFFORD & CO with over 8.28 million shares worth more than $665.08 million. As of 2024-06-30, BAILLIE GIFFORD & CO held 3.4425% of shares outstanding.
The other major institutional holder is PRIMECAP MANAGEMENT CO/CA/, with the holding of over 4.79 million shares as of 2024-06-30. The firm’s total holdings are worth over $384.89 million and represent 1.9922% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund and PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund . As of Dec 31, 2024 , the former fund manager holds about 0.95% shares in the company for having 2.27 shares of worth $261.64 million while later fund manager owns 1.12 shares of worth $128.99 million as of Jan 31, 2025 , which makes it owner of about 0.47% of company’s outstanding stock.
